Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Glucagon-like peptide 1 receptor36 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00391 | 35104330 | Diabetes Care | Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. | 2022 | Details |
| A00971 | 34915054 | J Hepatol | A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. | 2021 | Details |
| A01097 | 34870138 | Metabol Open | Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). | 2021 | Details |
| A01147 | 34855339 | FP Essent | Liver Disease: Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01387 | 34764398 | Sci Rep | A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). | 2021 | Details |
| A01761 | 34627692 | Nutr Metab Cardiovasc Dis | Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. | 2021 | Details |
| A02330 | 34416040 | Aliment Pharmacol Ther | Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. | 2021 | Details |
| A02574 | 34326020 | Surg Obes Relat Dis | Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease. | 2021 | Details |
| A02857 | 34214406 | Expert Opin Investig Drugs | Anti-diabetic drugs and NASH: from current options to promising perspectives. | 2021 | Details |
| A03040 | 34155798 | Liver Int | Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? | 2021 | Details |
| A06026 | 33036179 | J Clin Med | One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. | 2020 | Details |
| A06074 | 33015726 | Curr Diab Rep | Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A07241 | 32571083 | Ann Pharmacother | A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A07430 | 32502637 | Pharmacol Res | Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. | 2020 | Details |
| A07440 | 32496108 | Rev Esp Enferm Dig | The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A07629 | 32414752 | BMJ Open Gastroenterol | Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis. | 2020 | Details |
| A07979 | 32291277 | Diabetes Care | Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. | 2020 | Details |
| A08701 | 32017891 | Am J Med | Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? | 2020 | Details |
| A10476 | 31321014 | Ther Adv Chronic Dis | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. | 2019 | Details |
| A12223 | 30556145 | Hepatology | Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A12534 | 30405191 | Sci Rep | Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. | 2018 | Details |
| A14576 | 29344336 | Ther Adv Endocrinol Metab | Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. | 2017 | Details |
| A17056 | 28019064 | Hepatol Res | Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. | 2017 | Details |
| A18484 | 27101131 | Diabetologia | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. | 2016 | Details |
| A29839 | 33422984 | Eur J Med Chem | Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. | 2020 | Details |
| A30300 | 32682196 | Eur J Med Chem | A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice. | 2020 | Details |
| A43066 | 32646248 | Expert Opin Drug Discov | What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline. | 2020 | Details |
| A43419 | 31764586 | J Hypertens | Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. | 2020 | Details |
| A46216 | 20225248 | Hepatology | Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. | 2010 | Details |
| A48558 | 34137731 | Endocr Connect | How glucagon-like peptide 1 receptor agonists work. | 2021 | Details |
| A49962 | 35581956 | Hepatol Commun | Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. | 2022 | Details |
| A50123 | 35512974 | Fertil Steril | Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. | 2022 | Details |
| A50648 | 35316465 | Curr Diab Rep | Implementation of Cardiometabolic Centers and Training Programs. | 2022 | Details |
| A50654 | 35312970 | Diabetes Ther | Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study. | 2022 | Details |
| A51416 | 35680133 | Drug Metab Dispos | In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. | 2022 | Details |
| A51536 | 35491295 | Trends Endocrinol Metab | SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. | 2022 | Details |